Inovio Pharmaceuticals, Inc. (NASDAQ:INO)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a note issued to investors on Thursday. They presently have a $13.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 174.26% from the stock’s current price.

Other analysts also recently issued reports about the company. BidaskClub upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, September 9th. Maxim Group set a $12.00 price objective on Inovio Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 9th. Royal Bank of Canada assumed coverage on Inovio Pharmaceuticals in a research report on Wednesday, October 18th. They issued an “outperform” rating and a $11.00 price objective on the stock. Zacks Investment Research downgraded Inovio Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. Finally, Aegis restated a “buy” rating and issued a $14.00 price objective on shares of Inovio Pharmaceuticals in a research report on Tuesday, July 18th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $19.16.

Inovio Pharmaceuticals (INO) traded up $0.31 on Thursday, reaching $4.74. The company’s stock had a trading volume of 1,969,800 shares, compared to its average volume of 1,281,650. Inovio Pharmaceuticals has a one year low of $4.40 and a one year high of $9.86.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.15). The firm had revenue of $2.60 million for the quarter, compared to analysts’ expectations of $10.27 million. Inovio Pharmaceuticals had a negative return on equity of 72.19% and a negative net margin of 221.55%. The firm’s revenue for the quarter was down 79.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.28) earnings per share. equities analysts predict that Inovio Pharmaceuticals will post -0.88 EPS for the current year.

WARNING: This report was first reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/inovio-pharmaceuticals-inc-ino-stock-rating-reaffirmed-by-hc-wainwright/1696546.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in INO. Wasatch Advisors Inc. lifted its position in Inovio Pharmaceuticals by 43.6% during the second quarter. Wasatch Advisors Inc. now owns 2,610,818 shares of the biopharmaceutical company’s stock worth $20,469,000 after buying an additional 793,306 shares during the period. Vanguard Group Inc. lifted its position in Inovio Pharmaceuticals by 7.9% during the first quarter. Vanguard Group Inc. now owns 3,098,055 shares of the biopharmaceutical company’s stock worth $20,510,000 after buying an additional 226,861 shares during the period. Candriam Luxembourg S.C.A. purchased a new position in Inovio Pharmaceuticals during the second quarter worth about $1,411,000. GSA Capital Partners LLP purchased a new position in Inovio Pharmaceuticals during the second quarter worth about $1,035,000. Finally, Virtu KCG Holdings LLC purchased a new position in Inovio Pharmaceuticals during the second quarter worth about $556,000. Hedge funds and other institutional investors own 25.04% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.